News
Catch up on our latest updates
Innovation is one of the pillars of Eclipsebio’s culture, and our team of RNA experts is always developing new technologies and solutions. Learn more about our latest breakthroughs below.
RNA Delivery Prato 2026
Eclipsebio is proud to sponsor the 2026 RNA Delivery Prato meeting to discuss recent discoveries and challenges in RNA delivery.
Eclipsebio Expands eCOMPASS™ Platform with eSENSE Break™ to Map RNA Fragmentation at Nucleotide Resolution
Eclipsebio's eSENSE Break uses sequencing-based analytics to map RNA fragmentation and circular RNA nicking sites at single-nucleotide resolution.
2026 Data Catalyst Award Call for Applications
The Data Catalyst Award helps offset the cost of RNA profiling experiments using Eclipsebio's assays from our RNA profiling portfolio and contributes to the eVERSE database.
Eclipsebio Launches eCOMPASS™, an AI-Enabled Lab-in-the-Loop Platform for RNA Therapeutic Development
Eclipsebio's eCOMPASS platform combines AI-optimized design and sequencing-based analytics to produce successful RNA therapeutics efficiently.
2026 mRNA Innovators Award Call for Applications
The mRNA Innovators Award offers matching funds to design and validate a therapeutic of interest using Eclipsebio's design models and characterization methods.
Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics
Originally posted on Business Wire SAN DIEGO, January 26, 2026 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, today announced the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics. The acquisition accelerates Eclipsebio’s strategy to deliver an integrated, data-first platform to support RNA […]